Loading...
Eradication of Measurable Residual Disease in AML: A Challenging Clinical Goal
SIMPLE SUMMARY: Relapse is still a major problem in AML because it occurs in about 60–80% of patients, even those who have previously achieved complete remission (CR), defined by the presence of ≤5% bone marrow (BM) leukemic cells. Thus, since CR is unable to predict the relapse risk, significantly...
Na minha lista:
| Udgivet i: | Cancers (Basel) |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8268140/ https://ncbi.nlm.nih.gov/pubmed/34202000 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13133170 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|